dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Arbel Rubinstein, Tammi |
dc.contributor.author | Reuveni, Inbal |
dc.contributor.author | Hesin, Arkadi |
dc.contributor.author | Klein-Goldberg, Anat |
dc.contributor.author | Olauson, Hannes |
dc.contributor.author | Larsson, Tobias E. |
dc.contributor.author | Bosch Merino, Assumpció |
dc.contributor.author | Chillon Rodriguez, Miguel |
dc.date.accessioned | 2022-03-14T13:41:50Z |
dc.date.available | 2022-03-14T13:41:50Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Arbel Rubinstein T, Reuveni I, Hesin A, Klein-Goldberg A, Olauson H, Larsson TE, et al. A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy. Cancers (Basel). 2021 Dec;13(24):6297. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/7174 |
dc.description | Klotho; Càncer de pàncrees; Supressor del tumor |
dc.description.sponsorship | This project was funded by the The Sami and Tova Sagol Foundation for the Study of Aging, the Margaret Stultz foundation for Pancreatic Cancer Research, the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Ministerio de Ciencia e Innovación ‘Proyectos I+D+I 2019, to M.C., (grant number PID2019-104034RB-I00) and by the TASMC excellence fund. to I.W. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;13(24) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pàncrees - Càncer - Tractament |
dc.subject | Proteïnes supressores de tumors |
dc.subject.mesh | Pancreatic Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Tumor Suppressor Proteins |
dc.title | A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers13246297 |
dc.subject.decs | neoplasias pancreáticas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | proteínas supresoras de tumor |
dc.relation.publishversion | https://doi.org/10.3390/cancers13246297 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Arbel Rubinstein T, Reuveni I, Hesin A] Institute of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel. [Klein-Goldberg A] Institute of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel. [Olauson H] Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 14186 Stockholm, Sweden. [Larsson TE] Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 14186 Stockholm, Sweden. Department of Nephrology, Karolinska University Hospital, 17176 Stockholm, Sweden. [Bosch A] Klogenix Therapeutics Inc., Boston, MA 02116, USA. Institut de Neurociències, Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Mixta, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERNED, Instituto de Salud Carlos III, 28029 Madrid, Spain. [Chillón M] Klogenix Therapeutics Inc., Boston, MA 02116, USA. Institut de Neurociències, Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Mixta, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. ICREA, Institut Catalan Recerca Avançada, 08010 Barcelona, Spain |
dc.identifier.pmid | 34944918 |
dc.identifier.wos | 000747670700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |